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Abstract
Aim and clinical rationale for the study. It is now known that inflammation is i nvolved i n the p athophysiology of a cute 
ischaemic stroke (AIS). It has been proven that CRP and albumin alone are useful in predicting a prognosis for stroke patients. 
A combination of these two parameters, namely the ratio of CRP to albumin (CAR), is believed to be a more accurate indicator 
of inflammatory status than CRP or albumin alone, and may be more valuable than either of them separately in predicting the 
prognosis of ıschaemic stroke patients. However, the role of CAR as a predictor of mortality in patients with AIS remains unclear. 
Materials and methods. We retrospectively enrolled 260 patients who were referred to our clinic within the first 24 hours of 
symptom presentation and who were diagnosed with AIS between January 2015 and December 2018. The patient group was 
classified into two groups according to 90-day mortality. These groups were compared in terms of C-reactive protein, albumin, 
and CAR.
Results. The C-reactive protein and CAR values were higher, and the albumin level was lower, in non-surviving patients. The 
CAR value was also found to be a significant independent variable of 90-day mortality in patients with AIS (p < 0.001). The op-
timum cut-off value of CAR in predicting the 90-day mortality for patients with AIS was 0.50, with 64.1% sensitivity and 56.2% 
specificity.
Conclusions and clinical implications. Our study demonstrated that a high CAR value is an independent predictor of 90-day 
mortality in patients with AIS.
Key words: stroke, C-reactive protein to albumin ratio, mortality  
(Neurol Neurochir Pol 2019; 53 (3): 205–211)
Introduction
Acute Ischaemic Stroke (AIS) has a high rate of worldwide 
mortality and disability. Intravenous rtPA and endovascular 
therapy, which are effective treatments for ischaemic stroke, 
have narrow therapeutic windows and therefore patient selec-
tion criteria are important for these treatments. Also, there is 
as yet no treatment known to have neuroprotective proper-
ties. This situation prompted us to search for a biomarker to 
accelerate the diagnosis, predict the prognosis for patient 
selection, better understand the pathophysiology, and offer 
new treatment options. 
Inflammation is known to occur in the pathophysiology 
of ischaemic stroke [1, 2]. Necrotic cells, which are formed 
in the brain due to vascular occlusion, trigger inflammation. 
CRP and albumin is an acute phase protein. CRP is increased 
in inflammation, while albumin is decreased in inflammation 
as a negative phase reactant. 
Many studies have investigated the relationship between 
CRP and disease severity, functional outcome, in-hospital 
mortality, long-term mortality, and infarct volume in patients 
with ischaemic stroke [3–6]. Increased plasma levels of CRP 
may affect coagulation by inducing tissue factor expression 
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[7]. Activation of coagulation in patients with ischaemic stroke 
may increase mortality [8]. In addition to that, post-ischaemic 
inflammation increases neuronal injury [9], which may explain 
the poor outcome in patients with high CRP. 
Albumin, which is synthesised from the liver, acts as a car-
rier of endogenous and exogenous substances in the blood. 
The neuroprotective properties of albumin have been shown 
in animal models of ischaemic stroke [10]. It has also been 
reported to be an important inhibitor of platelet aggregation, 
scavenging free oxygen radicals, and acting as an antioxidant 
[11]. Albumin, like CRP, has been shown to be an independent 
prognostic factor, and has been used to predict recurrence, 
prognosis and mortality in ischaemic stroke [10, 12, 13].
Clinical rationale for the study
Although it has been shown that CRP and albumin 
individually are useful in predicting prognosis [14, 15], the 
combination of these two parameters, namely the ratio of 
CRP to albumin (CAR), has not been studied in detail. CAR 
may be a more accurate indicator of inflammatory status 
than CRP or albumin alone, and it may be of greatervalue 
than either of them separately in predicting the prognosis of 
ıschaemic stroke patients. Although CRP and albumin have 
been separately demonstrated to be associated with increased 
poor prognostic events in patients with ischaemic stroke, no 
study to date has investigated the prognostic importance of 
the CRP to albumin ratio in patients with ischaemic stroke. 
In this study, we hypothesise that an elevated CAR increases 
the risk of mortality in patients with ischaemic stroke. We 
assessed the association between the CAR at admission and 
90-day mortality in patients with ischaemic stroke.
Methods
Study design and data collectionThe files of patients who 
were admitted to the neurology clinic of Harran University 
Faculty of Medicine Training and Research Hospital, Sanlıurfa, 
Turkey between January 2015 and December 2018 with the 
diagnosis of acute ischaemic stroke (AIS) were retrospectively 
screened from electronic medical records. The diagnosis of 
AIS was based on the World Health Organisation definition 
[16]. Patients were aetiologically classified according to the 
Trial of Org 10,172 in Acute Stroke Treatment (TOAST) 
criteria: cardioembolic, atherosclerotic, small vessel/lacunar, 
and cryptogenic/others [17]. 
Exclusion criteria for the patients were the following: 
1) those patients with trauma or a history of surgery within 
the previous 12 months; 2) those with an active infection 
before stroke onset or within 72 h after admission; 3) previ-
ously known haematological disorders (e.g. anaemia, bleed-
ing disorder, leukaemia); 4) pre-existing kidney disease with 
serum creatinine > 1.5 mg/dL and pre-existing liver disease 
with abnormal liver function test; 5) intoxication; 6) patients 
with previous history of cerebrovascular diseases (ıschaemic 
and haemorrhagic); 7) a history of cancer at any time or the 
use of steroids or immunosuppressant agents within the previ-
ous 12 months; and 8) an absence of medical, demographic, 
clinical, laboratory, and/or radiological data. Our study was 
conducted in full accordance with the Declaration of Helsinki 
and was approved by the local ethics committee. Informed 
consent was not required due to its retrospective design.
Baseline clinical data including age, gender, and risk factors 
such as hypertension (HT), diabetes mellitus (DM), hyperlip-
idemia (HL), heart failure, and atrial fibrillation (AF) were re-
corded from patients’ medical records for all patients. HT was 
defined as systolic blood pressure (BP) ≥ 140 mmHg, and/or 
diastolic BP ≥ 90 mmHg, taking anti-hypertensive medications, 
and/or previously diagnosed hypertension. DM was defined as 
fasting serum glucose of  ≥ 126 mg/dL (7 mmol/L), non-fasting 
glucose of  ≥ 200 mg/dL (11.1 mmol/L), use of anti-diabetic 
medications, or a previously established diagnosis. HL was 
diagnosed if low-density lipoproteins (LDL)-cholesterol level 
was ≥ 100 mg/dL or in cases of the use of lipid-lowering agents 
after being diagnosed with HL. Congestive heart failure was 
defined as left ventricular ejection fraction ( LVEF) < 40% 
and typical symptoms e.g. breathlessness, ankle swelling, and 
fatigue [18]. Atrial fibrillation was defined as AF recorded at 
the time of the electrocardiography, or any previously known 
episode of AF.
Laboratory measurements
Venous blood samples for a complete blood count and 
serum chemistry, including serum albumin and CRP levels, 
were drawn when admitted to our hospital emergency service 
in all patients with a suspicion of acute ischaemic stroke. CAR 
was calculated by dividing the serum CRP level by the serum 
albumin level, while the neutrophil to lymphocyte ratio (NLR) 
was calculated by dividing the neutrophil count by the lympho-
cyte count. CAR, NLR, CRP, albumin, neutrophil, lymphocyte, 
and thrombocyte levels were recorded.
Statistical analysis
Data was expressed as the median for continuous variables 
and percentages for categorical variables. Mann-Whitney 
U test for continuous variables and x2 test for categorical 
variables were performed. To determine the factors associated 
with 90-day mortality, univariate analyses were performed 
firstly, followed by multivariate logistic regression analysis. 
Variables with P-values < 0.05 were put into the multivariate 
logistic regression model. To assess the association of the CRP/
albumin ratio with mortality outcome, the CRP/albumin ratio 
was examined as a continuous variable. To determine the best 
cutoff values for the albumin and CRP levels and CRP/albumin 
ratio, a receiver operating characteristic curve was generated 
and Youden’s index was calculated; sensitivities, specificities, 
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Table 1A. Baseline characteristics and laboratory data of categorical 
variables of patients with or without 90-day mortality







Male, n (%) 15 (33.3) 129 (60) 0.028
Hypertension, n (%) 17 (37.8) 131 (60.9) 0.0047
DM, n (%) 11 (24.4) 62 (28.8) 0.295
Hyperlipidemia, 
n (%)
4 (8.9) 65 (30.2) 0.029
Heart failure, n (%) 9 (20) 12 (6) 0.000
Coronary artery 
disease
4 (7) 14 (7) 0.326
Atrial fibrillation, 
n (%)































34 (75.6) 155 (72.1) 0.635
Stroke severity 
(NIHSS)
      Mild (0–4)
      Moderate (5–15)








Values are shown as median (interquartile range) or number (%) DM – diabetes mellitus; NIHSS – 
National Institutes of Health Stroke Scale
Table 1B. Baseline characteristics and laboratory data of continuous 
variables of patients with or without 90-day mortality







Age, years 75 (15) 66 (17) < 0.001
Albumin, g/dL 3.40 (0.4) 3.80 (0.6) < 0.001
CRP 1.32 (2.99) 0.53 (1.13) < 0.001
CRP / albumin 0.40 (0.87) 0.14 (0.31) < 0.001
NIHSS 7 (6) 13 (9) < 0.001
LDL, mg/dL 141 (108.05) 117 (72) 0.20
HDL, mg/dL 39.3 (11) 39 (11) 0.117
Triglyceride, mg/dL 133 (41.46) 169 (80) 0.016
Total cholesterol,  
mg/dL
183 (24.6) 183 (46) 0.875
Creatinine 0.75 (0.3) 0.81 (0.27) 0.875
Glucose,  mg/dL 151 (50) 123 (58) 0.022
White blood cell, 
103/mc
11.5 (4.56) 10.1 (3.63) 0.006
Platelet, 103/mc 240 (108) 256 (105) 0.263
Haemoglobin, g/dL 13.4 (2.34) 14 (2.97) 0.014
Neurophil / lymp-
hocyte
5.51 (5.67) 3.8 (3.12) < 0.001
Platelet / lymphocyte 152.27 (142.87) 129.5 (90.62) 0.088
Values are shown as median (interquartile range) LDL – low density lipo-
protein; HDL – high density lipoprotein; CRP – C-reactive protein; NIHSS 
– National Institutes of Health Stroke Scale
positive and negative predictive values, and their 95% CIs were 
also calculated. We determined predictive performance using 
receiver operating characteristic curves with logistic regression 
models to compare and assess for equality of the area under 
the curve using the DeLong test. Statistical analyses were per-
formed by the use of SPSS, NSCC, Stata, and Gretl. P values 
≤ 0.05 were considered statistically significant.
Results
A total of 413 patients with suspected acute ischaemic 
stroke were admitted to our hospital during the study period. 
Of those, 153 were excluded because they had a history of 
previous stroke (n: 19), had liver or kidney disease (n: 20), 
were admitted more than 24 hours after the onset of symptoms 
(n: 52), had a recent history of surgery, acute infection and 
malignancy (n: 14), or had missing data (n: 48). 
The remaining 260 patients were finally included in this 
study. The median age was 68 (18) years and 144 patients 
(55.4%) were male. Forty-five patients (17.3%) died within 
90 days. Female were more common in the non-survivor 
group. Hypertension was the most common comorbidity. 
A history of atrial fibrillation and heart failure were more 
common among non-survivors, while hypertension was more 
common among survivors. There was no association between 
CAR and stroke subtypes. Baseline characteristics and labora-
tory data of categorical variables are set out in Table 1A and 
continuous variables are set out in Table 1B.
The CAR ranged from zero to 3.47 [0.170 (0.36)]. The CAR 
was higher in non-survivors than in survivors [0.40 (0.87) vs 
0.14 (0.31)]. In the univariate analyses, age, female sex, hy-
pertension, hyperlipidemia, atrial fibrillation, congestive heart 
failure, stroke severity, triglyceride, white blood cell count, 
haemoglobin level, neutrophil count, total cholesterol, CRP, 
albumin, CAR, neutrophil to lymphocyte ratio, and platelet to 
lymphocyte ratio revealed statistically significant associations 
with 90-day mortality. After adjusting for all these variables, 
the CAR still revealed an association with 90-mortality of 
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Table 2. Odds ratios for all-cause 90 day mortality events
Univariate p Multivariate p
Odds ratio CI lower CI upper Odds ratio CI lower CI upper
Age  1.067 1.033 1.101  0.000 1.064 1.010 1.122 0.020
Sex, female  3 0.0681 0.1985 0.000 4.437 1.265 15.560 0.020
Diabetes mellitus 0.798 0.3805 1.675 0.552
Hypertension 0.389 0.2008 0.755 0.005 0.891 0.282 2.820 0.844
Hyperlipidemia 0.225 0.078 0.655 0.006 0.524 0.086 3.180 0.482
Coronary artery disease 1.401 0.439 4.472 0.569  
Atrial fibrillation 2.41 1.140 5.097 0.021 0.160  0.022 1.169 0.071
Congestive heart failure 8.323 3.254 21.289 0.000 3.176 0.464 21.734 0.239






5.577 1.29 24.16 0.022 13.918 1.591 121.744 0.017
Stroke severity (NIHSS)
Severe (> 16)






0.440 0.149 1.301 0.138
Stroke aetiology (small 
vessel/lacunar)
0.380 0.149 1.301 0.123
Stroke aetiology (crypto-
genic/other)
0.627 0.316 1.247 0.183  
LDL cholesterol, mg/dL 1.001 0.998 1.012 0.155  
HDL cholesterol, mg/dL 1.010 0.985 1.037 0.448
Triglyceride, mg/dL 0.994 0.988 0.999 0.018 0.996 0.807  1.009 0.664
White blood cell, 103/mL 1.199 1.05 1.367 0.006 1.749 0.997  4.335 0.227
Haemoglobin, g/dL 0.837 0.721 0.973 0.020 1.110 0.629  1.527 0.522
Platelet count, 103/mL 1.000 0.997 1.003 0.931  
Mean platelet volume, fL 1.016 0.838 1.233 0.869 
Neutrophil count, 103/mL 1.226 1.085 1.385 0.001 0.652 0.995  1.513 0.320
Lymphocyte count, 103/
mL
0.725 0.508 1.035 0.077
Glucose, mg/dL 1.003 0.998 1.007 0.297  
Creatinine, mg/dL 1.351 0.457 3.995 0.586
Total cholesterol, mg/dL 0.991 0.983 0.999 0.026 0.975 0.098  1.007 0.055
CRP 1.672 1.355 2.064 0.000 1.771 1.010  2.486 0.001
Albumin 0.279 0.138 0.566 0.000 0.325 0 .996  1.075 0.066
CRP/albumin 4.998 2.497 10.005 0.000 6.345 2.201 18.295 0.001
Neutrophil to lymphocyte 
ratio
1.138  1.059 1.223 0.000 0.835 0.660 1.057 0.134
CRP – C-reactive protein; CI – confidence interval
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stroke patients. The CAR showed an association with 90-day 
mortality (odds ratio, 6.345; 95% CI, 2.201 to 18.295) (Tab. 2).
Table 3 reveals the sensitivity, specificity, positive and 
negative predictive values of the albumin level, CRP level and 
CAR. The best cutoff value of the CAR was 0.50, with 64.1% 
sensitivity and 56.2%  specificity. The area under the curve 
of the CAR was greater than that of albumin and CRP alone 
(Tab. 4, Fig. 1). 
Discussion
Ourstudy showed that CAR at the time of admission is an 
independent predictor of mortality in the third month of acute 
ischaemic stroke patients. To the best of our knowledge, CAR 
has not been previously evaluated in predicting prognosis in 
patients with acute ischaemic stroke. The present study is the 
first to show that CAR is an independent predictor of three-
-month mortality of ischaemic stroke patients. In addition, 
CAR may have a greater prognostic value than CRP and 
albumin alone. The odds ratio of CAR (6.35) was higher than 
the CRP’s odds ratio (1.8) for predicting three month morta-
lity. For intance, after adjusting for all confounding factors, 
every whole-number increase in CAR increased by 6.35 the 
probability of mortality in the third month. On the other 
hand, while each whole-number increase in CRP increased 
by 1.8, each whole number decrease in albumin level affected 
mortality by 3.07 (Tab. 2).
If a patient had a CAR of > 0.5, the risk of 90-day mortality 
was 43.1%. If a patient had a CAR of < 0.5, the probability of 
survival at 90 days was 87.8% (Tab. 3).
CRP and albumin are both independently affected by 
inflammatory conditions, As CRP increases in inflammation, 
albumin metabolism increases and synthesis decreases [19]. 
Albumin is also affected by nutritional deficiency. With incre-
asing age, malnutrition increases and this causes albumin de-
ficiency [20]. We tried to exclude conditions that might affect 
CRP and albumin, but we could not exclude chronic hypoal-
bumin due to a lack of information about the nutritional status 
of patients. In our study, similar to previous studies, elevated 
CRP level was statistically significant at 90-day mortality 
(p: 0.001), and decreasing albumin did not reach significance 
but trended toward significance at three month mortality 
(p: 0.06) (Tab. 2). CAR, which collects CRP and albumin 
under a single index, has been recently considered as a novel 
marker. In different disease groups, especially in prognostic 
predictive studies, some have used CAR as only one marker, 
while others have compared the values of CAR to those of 
albumin and CRP alone to predict prognosis. 
In our study, CRP was found to be statistically significant. 
Albumin did not reach significance but trended toward signi-
ficance. As shown in ROC analysis, we found CAR was more 
significant compared to the area under the curve (Tab. 4). 
The fact that albumin was not statistically significant may be 
due to the limited number of patients. Furthermore, although 
albumin is an acute phase reactant, its response is slightly 
delayed. In this study, we obtained albumin at the time of 
admission, and this may be another reason why albumin did 
not reach statistical significance.
Table 3. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of albumin, CRP, and CRP / albumin ratio (CAR)
Cutoff Sensitivity Specificity PPV NPV
Albumin 2.2 0.366 (0.225–0.069) 0.501 (0.362–0.068) 0.101 (0.081–0.122) 0.771 (0.743–0.800)
CRP 1.92 0.560 (0.525–0.018) 0.656 (0.616–0.020) 0.362 (0.331–0.394) 0.883 (0.880–0.886)
CRP / albumin ratio 0.50 0.641 (0.609–0.016) 0.562 (0.525–0.019) 0.431 (0.386–0.477) 0.878 (0.874–0.883)
Table 4. Area under curve of CRP, albumin, and CRP / albumin ratio






CRP 0.689 0.048 0.000 0.595 0.783




0.696 0.047 0.000 0.604 0.788
Figure 1. Receiver operating curve of CRP, albumin level and CAR in 
predicting 90-day mortality
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In a systematic review of five studies, CRP elevation was 
significantly related to functional outcome in ischaemic stroke 
[21]. One study found that follow-up CRP had a greater pre-
dictive value than that of CRP on admission [22]. In another 
study, CRP taken within two weeks of admission to hospital 
was associated with poor functional disability at one year [5]. 
We thought that the marker (CAR) obtained at the time of 
admission could be more useful in making a quick decision 
about the treatment to be chosen. So in this study we used 
admission CRP and albumin to predict 90-day mortality.
CAR is a new inflammation marker and is believed to 
reflect inflammatory status better than albumin and CRP 
alone. In our study, the predictive accuracy of CAR was better 
than that of CRP and albumin, according to the comparison 
of ROC curves. Recently, the relationship between CAR and 
critical diseases, malignancy, post-op patients, and cardiova-
scular diseases has been studied [23, 24]. CAR has emerged 
as an independent indicator of poor prognosis in various 
malignancies, including liver, lung, pancreatic, oesophageal 
and cervical malignancies [25]. A significant relationship was 
found between the CAR and the severity of coronary artery 
disease in patients with acute coronary syndrome [26]. One 
study showed that CAR measured after admission to the 
intensive care unit was an independent risk factor for 30-day 
and one-year mortality in postoperative patients [27]. To the 
best of our knowledge, no previous study has investigated the 
relationship between prognosis, disease severity or mortality, 
and CAR in stroke patients. 
Neutrophil to lymphocyte ratio (NLR) has emerged as 
a novel marker of systemic inflammation. Previous studies 
have reported that NLR was associated with poor outcomes 
and predicted short-term mortality in patients with AIS [28]. 
In our study, although NLR was associated with an increased 
risk of mortality in univariate analysis, it did not reach stati-
stical significance in multivariate analysis. However, CAR was 
an independent predictor of mortality in multivariate analysis. 
Therefore, CAR may be more valuable than NRL in predicting 
prognosis in acute ischaemic stroke. In accordance with the 
previous report, age, sex (female) and stroke severity also affec-
ted 90-day mortality independently ın our study [29] (Tab. 2). 
In this study, we could not detect a relationship between 
stroke subtypes and CAR. For this reason, it is not yet clear 
how CAR works in each stroke subtype. In order to clarify the 
relationship between CAR and stroke subtypes, we think that 
there is a need for further studies with broader participation.
The primary limitation of this study is its retrospective 
observational design from a single centre. We do not know 
the exact cause of death of our study population, and cannot 
provide serial measurements of CRP and albumin. Also in our 
study we used conventional CRP rather than hsCRP, which 
can detect smaller changes in inflammation. 
In conclusion, CAR at admission to hospital was associated 
with 90-day mortality among stroke patients. CAR may serve 
as a surrogate marker of disease severity. Moreover, CAR at 
the time of admission may be more helpful in predicting 
mortality at three months compared to CRP. A high CAR at 
initial presentation to the hospital in a stroke patient may aid 
decision making regarding treatment. However, the progno-
stic value of CAR needs to be verified by larger studies with 
different populations.
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